Vertex Pharmaceuticals
VRTX
706 hedge funds and large institutions have $40.4B invested in Vertex Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 93 funds opening new positions, 233 increasing their positions, 265 reducing their positions, and 77 closing their positions.
21% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 77
1% more funds holding
Funds holding: 696 → 706 (+10)
0.71% more ownership
Funds ownership: 94.74% → 95.46% (+0.71%)
0% more funds holding in top 10
Funds holding in top 10: 16 → 16 (0)
2% less call options, than puts
Call options by funds: $403M | Put options by funds: $412M
12% less repeat investments, than reductions
Existing positions increased: 233 | Existing positions reduced: 265
13% less capital invested
Capital invested by funds: $46.7B → $40.4B (-$6.24B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$418M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$415M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$378M |
| 4 |
Jennison Associates
New York
|
+$128M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$118M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$241M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$154M |
| 3 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$117M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$102M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$100M |
VRTX Hedge Fund Activity: Q4 2018 in Review
706 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2018, worth a combined $40.4B — down 13% from $46.7B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new VRTX positions and 77 closed out — a net gain of 16 holders — while 233 added to existing stakes and 265 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $418M. The largest seller was Ameriprise, cutting an estimated $241M.
- 706 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2018, up from 696 in Q3 2018.
- Funds reported $40.4B of Vertex Pharmaceuticals stock for Q4 2018, down 13% quarter-over-quarter.
- 93 funds opened new Vertex Pharmaceuticals positions in Q4 2018 and 77 closed out, a net change of +16 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2018 was Fidelity Investments, an estimated $418M added.
- The largest Vertex Pharmaceuticals seller in Q4 2018 was Ameriprise, an estimated $241M sold.
Based on aggregated 13F filings for Q4 2018.